Madrigal pharmaceuticals announces fda approval of rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (nash) with moderate to advanced liver fibrosis

Conshohocken, pa., march 14, 2024 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq:mdgl), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (nash), today announced that the u.s. food and drug administration (fda) has granted accelerated approval for rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults with noncirrhotic nash with moderate to advanced liver fibrosis (consistent with stages f2 to f3 fibrosis). continued approval for this indication may be contingent upon verification and description of clinical benefit in ongoing confirmatory trials.
MDGL Ratings Summary
MDGL Quant Ranking